|Free Dividend Report|
|Stock Splits Calendar|
|VRTX Stock Split History|
|Preferred Stock Newsletter|
|VRTX Options Chain|
|Stock Message Boards|
Vertex Pharmaceuticals (VRTX) has 1 split in our Vertex Pharmaceuticals stock split history database. The split for VRTX took place on August 24, 2000. This was a 2 for 1 split, meaning for each share of VRTX owned pre-split, the shareholder now owned 2 shares. For example, a 1000 share position pre-split, became a 2000 share position following the split.
When a company such as Vertex Pharmaceuticals splits its shares, the market capitalization before and after the split takes place remains stable, meaning the shareholder now owns more shares but each are valued at a lower price per share. Often, however, a lower priced stock on a per-share basis can attract a wider range of buyers. If that increased demand causes the share price to appreciate, then the total market capitalization rises post-split. This does not always happen, however, often depending on the underlying fundamentals of the business.
Looking at the Vertex Pharmaceuticals stock split history from start to finish, an original position size of 1000 shares would have turned into 2000 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into Vertex Pharmaceuticals shares, starting with a $10,000 purchase of VRTX, presented on a split-history-adjusted basis factoring in the complete Vertex Pharmaceuticals stock split history.
Growth of $10,000.00
Without Dividends Reinvested
|Average Annual Total Return:||21.36%|
|About Vertex Pharmaceuticals|
|Vertex Pharmaceuticals develops and commercializes therapies for the treatment of cystic fibrosis (CF) and developing research and development programs in other indications. Co.'s marketed products are TRIKAFTA/KAFTRIO (elexacaftor/tezacaftor/ivacaftor and ivacaftor), SYMDEKO/SYMKEVI (tezacaftor in combination with ivacaftor), ORKAMBI (lumacaftor in combination with ivacaftor) and KALYDECO (ivacaftor), which are approved to treat people with CF who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene. Co. is co-developing CTX001, an investigational CRISPR/Cas9-based gene-editing therapy for sickle cell disease and transfusion-dependent beta thalassemia. According to our Vertex Pharmaceuticals stock split history records, Vertex Pharmaceuticals has had 1 split.|
|VRTX Split History Table|
|08/24/2000||2 for 1|
|Healthcare Stock Splits|
|VRTX is categorized under the Healthcare sector; below are some other companies in the same sector that also have a history of stock splits:
Also explore: VRTX shares outstanding history